BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a common liver disease associated with obesity and diabetes. NASH is a progressive disorder that can lead to cirrhosis and liver failure. Insulin resistance and oxidative stress are thought to play important roles in its pathogenesis. There is no definitive treatment for NASH. OBJECTIVES: PIVENS is conducted to test the hypotheses that treatment with pioglitazone, a thiazolidinedione insulin sensitizer, or vitamin E, a naturally available antioxidant, will lead to improvement in hepatic histology in non-diabetic adults with biopsy proven NASH. DESIGN: PIVENS is a randomized, multicenter, double-masked, placebo-controlled trial to evaluate whether 96 weeks of treatment with pioglitazone or vitamin E improves hepatic histology in non-diabetic adults with NASH compared to treatment with placebo. Before and post-treatment liver biopsies are read centrally in a masked fashion for an assessment of steatohepatitis and a NAFLD Activity Score (NAS) consisting of steatosis, lobular inflammation, and hepatocyte ballooning. The primary outcome measure is defined as either an improvement in NAS by 2 or more in at least two NAS features, or a post-treatment NAS of 3 or less, and improvement in hepatocyte ballooning by 1 or more, and no worsening of fibrosis. METHODS:PIVENS enrollment started in January 2005 and ended in January 2007 with 247 patients randomized to receive either pioglitazone (30 mg q.d.), vitamin E (800 IU q.d.), or placebo for 96 weeks. Participants will be followed for an additional 24 weeks after stopping the treatment. The study protocol incorporates the use of several validated questionnaires and specimen banking. This protocol was approved by all participating center Institutional Review Boards (IRBs) and an independent Data and Safety Monitoring Board (DSMB) which was established for monitoring the accumulated interim data as the trial progresses to ensure patient safety and to review efficacy as well as the quality of data collection and overall study management. (ClinicalTrials.gov number, NCT00063622).
RCT Entities:
BACKGROUND:Non-alcoholic steatohepatitis (NASH) is a common liver disease associated with obesity and diabetes. NASH is a progressive disorder that can lead to cirrhosis and liver failure. Insulin resistance and oxidative stress are thought to play important roles in its pathogenesis. There is no definitive treatment for NASH. OBJECTIVES: PIVENS is conducted to test the hypotheses that treatment with pioglitazone, a thiazolidinedioneinsulin sensitizer, or vitamin E, a naturally available antioxidant, will lead to improvement in hepatic histology in non-diabetic adults with biopsy proven NASH. DESIGN: PIVENS is a randomized, multicenter, double-masked, placebo-controlled trial to evaluate whether 96 weeks of treatment with pioglitazone or vitamin E improves hepatic histology in non-diabetic adults with NASH compared to treatment with placebo. Before and post-treatment liver biopsies are read centrally in a masked fashion for an assessment of steatohepatitis and a NAFLD Activity Score (NAS) consisting of steatosis, lobular inflammation, and hepatocyte ballooning. The primary outcome measure is defined as either an improvement in NAS by 2 or more in at least two NAS features, or a post-treatment NAS of 3 or less, and improvement in hepatocyte ballooning by 1 or more, and no worsening of fibrosis. METHODS: PIVENS enrollment started in January 2005 and ended in January 2007 with 247 patients randomized to receive either pioglitazone (30 mg q.d.), vitamin E (800 IU q.d.), or placebo for 96 weeks. Participants will be followed for an additional 24 weeks after stopping the treatment. The study protocol incorporates the use of several validated questionnaires and specimen banking. This protocol was approved by all participating center Institutional Review Boards (IRBs) and an independent Data and Safety Monitoring Board (DSMB) which was established for monitoring the accumulated interim data as the trial progresses to ensure patient safety and to review efficacy as well as the quality of data collection and overall study management. (ClinicalTrials.gov number, NCT00063622).
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Arun J Sanyal; Pouneh S Mofrad; Melissa J Contos; Carol Sargeant; Velimir A Luketic; Richard K Sterling; R Todd Stravitz; Mitchell L Shiffman; John Clore; Alan S Mills Journal: Clin Gastroenterol Hepatol Date: 2004-12 Impact factor: 11.382
Authors: Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley Journal: Hepatology Date: 2010-09 Impact factor: 17.425
Authors: Lauren N Bell; Jiangxia Wang; Sriya Muralidharan; Sadhana Chalasani; Allison M Fullenkamp; Laura A Wilson; Arun J Sanyal; Kris V Kowdley; Brent A Neuschwander-Tetri; Elizabeth M Brunt; Arthur J McCullough; Nathan M Bass; Anna Mae Diehl; Aynur Unalp-Arida; Naga Chalasani Journal: Hepatology Date: 2012-08-21 Impact factor: 17.425
Authors: Raj Vuppalanchi; Robert J Gould; Laura A Wilson; Aynur Unalp-Arida; Oscar W Cummings; Naga Chalasani; Kris V Kowdley Journal: Hepatol Int Date: 2011-05-10 Impact factor: 6.047
Authors: An Tang; Justin Tan; Mark Sun; Gavin Hamilton; Mark Bydder; Tanya Wolfson; Anthony C Gamst; Michael Middleton; Elizabeth M Brunt; Rohit Loomba; Joel E Lavine; Jeffrey B Schwimmer; Claude B Sirlin Journal: Radiology Date: 2013-02-04 Impact factor: 11.105
Authors: Ju Dong Yang; Manal F Abdelmalek; Cynthia D Guy; Ryan M Gill; Joel E Lavine; Katherine Yates; Jagpal Klair; Norah A Terrault; Jeanne M Clark; Aynur Unalp-Arida; Anna Mae Diehl; Ayako Suzuki Journal: Clin Gastroenterol Hepatol Date: 2016-08-12 Impact factor: 11.382